Abstract
A previous phenotypic screening campaign led to the identification of a quinazoline derivative with promising in vitro activity against Schistosoma mansoni. Follow-up studies of the antischistosomal potential of this candidate are presented here. The in vivo studies in a S. mansoni mouse model show a significant reduction of total worms and a complete disappearance of immature eggs when administered concomitantly with praziquantel in comparison with the administration of praziquantel alone. This fact is of utmost importance because eggs are responsible for the pathology and transmission of the disease. Subsequently, the chemical optimisation of the structure in order to improve the metabolic stability of the parent compound was carried out leading to derivatives with improved drug-like properties. Additionally, the putative target of this new class of antischistosomal compounds was envisaged by using computational tools and the binding mode to the target enzyme, aldose reductase, was proposed.
Highlights
Schistosomiasis is a parasitic infectious disease caused by a trematode belonging to Schistosoma spp
The results indicate that the compound becomes extensively metabolised through phase-I but not through phase-II metabolism
The compound was extensively metabolised through phase-I metabolism (Table 1)
Summary
Schistosomiasis is a parasitic infectious disease caused by a trematode belonging to Schistosoma spp. Part of the eggs is passed in the faeces or urine to continue the parasite’s life cycle by contaminating water while most become trapped in body tissues causing immune-inflammatory responses and progressive damage to organs[1]. This neglected tropical disease is endemic in a number of tropical and subtropical countries representing a serious health problem especially in poor communities. The disease has recently reached Europe, demonstrating the possibility to emerge in new geographical areas previously unknown related to migration movements and parasite genetic variants[2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Enzyme Inhibition and Medicinal Chemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
